Compare Iamgold Corporation Ordinary Shares (IAG) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iamgold Corporation Ordinary Shares vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Iamgold Corporation Ordinary Shares trades at $17.22 (market cap $10.39B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Iamgold Corporation Ordinary Shares is far larger — about 10.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Iamgold Corporation Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iamgold Corporation Ordinary Shares for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IAG | MRVI | |
|---|---|---|
Market Cap | $10.39B | $972.90M |
Volume | 2,784,290 | 4,325,710 |
Sector | Basic Materials | Health |
52-Week High | $24.57 | $9.00 |
52-Week Low | $10.96 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.43B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAG trades at $18.27, down 1.62% today, with technical indicators showing a neutral bias. The company demonstrates strong fundamentals with a P/E of 9.23, net income margin of 31.4%, and ROE of 29.53%. Recent earnings show mixed results with two beats and one miss in the last three quarters. Analyst consensus is moderately bullish with a $22.00 price target, representing 20% upside potential from current levels.
IAG presents a compelling value opportunity with attractive valuation metrics and strong profitability. Key catalysts include Q3 2026 earnings release in November and operational optimization initiatives. Risks include commodity price volatility, execution challenges at mining operations, and potential cost pressures from rising fuel prices that could impact profitability.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iamgold Corporation Ordinary Shares
IAMGOLD is a gold mining company with operations in Canada. It also explores and develops gold properties.
Read more on IAG →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
